Ranbaxy Launches Daiichi-Sankyo's Antihypertensive

One of BMI's core views for the pharmaceutical industry is that Africa represents a long-term challenge and opportunity. The continent has a combined population of 1bn people and GDP of US$1,500bn. However, outside South Africa and certain other countries, pharmaceutical companies remain reluctant to launch products or invest in manufacturing plants. Fundamental disincentives include low per-capita incomes, a young population, inadequate healthcare infrastructure, unenforced regulations and a high prevalence of counterfeit medicines.

To read the full article, please choose one of the following options: